AbbVie will write off $3.5 billion related to its $8.7 billion investment in Cerevel Therapeutics following the failure of the company’s key schizophrenia drug, emraclidine, The Wall Street Journal reported Jan. 10.
Read the full post on Becker's Hospital Review | Healthcare News & Analysis
